Articles producció científica> Bioquímica i Biotecnologia

Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial

  • Dades identificatives

    Identificador: imarina:9216837
    Autors:
    Becerra-Tomas, NereaRuiz-Canela, MiguelHernandez-Alonso, PabloBullo, MonicaLi, JunGuasch-Ferre, MartaToledo, EstefaniaClish, Clary BEstruch, RamonRos, EmilioFito, MontserratLee, Chih-HaoPierce, KerryAros, FernandoSerra-Majem, LluisLiang, LimingRazquin, CristinaGomez-Gracia, EnriqueMartinez-Gonzalez, Miguel AHu, Frank BCorella, DoloresSalas-Salvado, Jordi
    Resum:
    The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR (for 1 SD increase): 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.
  • Altres:

    Autor segons l'article: Becerra-Tomas, Nerea; Ruiz-Canela, Miguel; Hernandez-Alonso, Pablo; Bullo, Monica; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary B; Estruch, Ramon; Ros, Emilio; Fito, Montserrat; Lee, Chih-Hao; Pierce, Kerry; Aros, Fernando; Serra-Majem, Lluis; Liang, Liming; Razquin, Cristina; Gomez-Gracia, Enrique; Martinez-Gonzalez, Miguel A; Hu, Frank B; Corella, Dolores; Salas-Salvado, Jordi
    Departament: Bioquímica i Biotecnologia
    e-ISSN: 2218-1989
    Autor/s de la URV: Becerra Tomás, Nerea / Bulló Bonet, Mònica / Salas Salvadó, Jorge
    Paraules clau: Uric-acid Predimed study Heart failure Glycolysis Glucose Biomarkers Atrial fibrillation
    Resum: The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR (for 1 SD increase): 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.
    Àrees temàtiques: Molecular biology Medicina ii Farmacia Endocrinology, diabetes and metabolism Ciências biológicas ii Ciências biológicas i Biotecnología Biochemistry & molecular biology Biochemistry
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: nerea.becerra@urv.cat monica.bullo@urv.cat jordi.salas@urv.cat
    Identificador de l'autor: 0000-0002-4429-6507 0000-0002-0218-7046 0000-0003-2700-7459
    Data d'alta del registre: 2024-10-12
    Volum de revista: 11
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.mdpi.com/2218-1989/11/5/306
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Metabolites. 11 (5): 306-
    Referència de l'ítem segons les normes APA: Becerra-Tomas, Nerea; Ruiz-Canela, Miguel; Hernandez-Alonso, Pablo; Bullo, Monica; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary B; Es (2021). Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites, 11(5), 306-. DOI: 10.3390/metabo11050306
    DOI de l'article: 10.3390/metabo11050306
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2021
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Biochemistry,Biochemistry & Molecular Biology,Endocrinology, Diabetes and Metabolism,Molecular Biology
    Uric-acid
    Predimed study
    Heart failure
    Glycolysis
    Glucose
    Biomarkers
    Atrial fibrillation
    Molecular biology
    Medicina ii
    Farmacia
    Endocrinology, diabetes and metabolism
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
    Biochemistry & molecular biology
    Biochemistry
  • Documents:

  • Cerca a google

    Search to google scholar